CAS 1420477-60-6

General Information

Acalabrutinib is an oral inhibitor of Bruton’s tyrosine kinase. Acalabrutinib is used in treatment of mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used to treat chronic lymphocytic leukemia (CLL; a type of cancer in which the bone marrow makes too many lymphocytes) and small lymphocytic lymphoma (SLL: where cancer cells are found mostly in the lymph nodes).
Acalabrutinib works by blocking the action of the abnormal protein that signals cancer cells to multiply which helps stop the spread of cancer cells.

About the API

Systematic name 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
Molecular Formula C26H23N7O2
Molecular Weight 465.5 g/mol
Therapeutic category Oncology
Available formulations Oral Solid